CorMedix Inc. filings document the regulatory record of a Nasdaq-listed biopharmaceutical company commercializing DefenCath and a broader portfolio of institutional-care specialty pharmaceuticals. Form 8-K reports cover operating results, financial condition, corporate presentations, material-event disclosures, clinical or regulatory updates and business developments following the completed Melinta Therapeutics acquisition.
Proxy statements describe shareholder voting matters, board and governance practices, equity incentive plan proposals, certificate of incorporation matters and preferred-stock voting provisions. Acquisition-related amendments include financial statements of the acquired business and pro forma financial information, while the company’s securities disclosures identify CRMD common stock listed on the Nasdaq Global Market.
CorMedix Inc. (CRMD) has a shelf prospectus for resale of up to 6,323,833 shares of common stock by selling securityholders; the company will not receive proceeds from those sales. The shares include amounts issued under a Merger Agreement and potential milestone shares issuable under a Collaboration and Purchase Agreement (CPA) through June 30, 2029, with milestone share valuation tied to a five-day VWAP on the Nasdaq prior to each milestone. Named selling holders include Deerfield Private Design Fund IV, L.P. and Deerfield Private Design Fund III, L.P., with specified allocations of Merger and potential milestone shares. The Nasdaq Global Market ticker is CRMD. The prospectus refers investors to the Risk Factors section and incorporated reports for further details.
CorMedix Inc. filed Amendment No. 1 to a prior current report to provide additional financial information related to its completed acquisition of Melinta Therapeutics, LLC. The amendment relates to the merger that closed on August 29, 2025 under the Agreement and Plan of Merger dated August 7, 2025.
The filing adds audited consolidated financial statements of Melinta for the years ended December 31, 2024 and 2023, unaudited condensed consolidated financial statements for the six months ended June 30, 2025, and unaudited pro forma condensed combined financial information for the year ended December 31, 2024 and the six months ended June 30, 2025. These materials are included as Exhibits 99.2, 99.3 and 99.4, along with an auditor consent.
CorMedix Inc. director Gregory Scott Duncan reported insider transactions on 09/16/2025. The filing shows an acquisition of 13,333 shares of common stock at $8.32 per share, bringing his total common stock beneficially owned to 38,333 shares. The report also lists a derivative transaction showing 13,333 stock options with an $8.32 exercise price, exercisable beginning 01/10/2031, and 6,667 derivative shares beneficially owned following the transaction. The form notes these options were granted 01/11/2021 and vest monthly with full vesting after one year, subject to continued board service.
Alan W. Dunton, a director of CorMedix Inc. (CRMD), reported same-day transactions on 09/12/2025 in the company's common stock and related options. He exercised a stock option with a $3.55 exercise price to acquire 10,000 shares, increasing his direct holdings to 50,250 shares, and sold 10,000 shares the same day in multiple trades at a weighted average price of $13.13, reducing his direct holdings to 40,250 shares. The Form 4 discloses the option grant date of 03/05/2024 and that those options vest monthly with full vesting one year after grant. The filing is signed and dated 09/16/2025.
CorMedix Inc. is soliciting votes at a virtual special meeting to approve three proposals: removal of an exchange cap, an amendment to its 2022 Stock Incentive Plan to increase authorized shares from 8,160,000 to 12,472,000, and an adjournment proposal. The amendment would make the additional shares available for a variety of equity awards including incentive stock options, SARs, restricted stock and RSUs to attract and retain employees, consultants and directors. The proxy discloses potential contingent consideration tied to a prior transaction including up to $25,000,000 in milestone payments payable in cash, stock or warrants and references Merger Warrants and Notes. The company reported the Nasdaq closing price of its common stock as $12.75 on September 8, 2025. The materials explain voting mechanics, broker non-vote treatment, beneficial ownership disclosure for certain holders and deadlines for 2026 stockholder proposals.
CorMedix Inc. insider Beth Zelnick Kaufman reported multiple transactions on 09/09/2025. She acquired 50,000 shares by exercising options at an exercise price of $3.30 (options originally granted 12/12/2023, vesting over four years). On the same date she disposed of 49,600 shares at a weighted average price of $13.41 and 400 shares at $12.82. Following these trades her beneficial ownership is reported as 180,418 shares.
Elizabeth Hurlburt, Chief Operating Officer of CorMedix Inc. (CRMD), reported option exercises and subsequent open-market sales in September 2025. On 09/09/2025 she exercised 12,876 stock options at an exercise price of $1.45 and sold 12,876 shares at a weighted average price of $13.51. On 09/11/2025 she exercised 41,121 options at $1.45 and sold 41,121 shares at a weighted average price of $13.08. Following these transactions her beneficial ownership is reported as 176,990 shares. The exercised options were originally granted 03/19/2018 with scheduled vesting and milestone-based vesting for remaining amounts.
CorMedix Inc. (CRMD) submitted a Form 144 notice reporting a proposed sale of 50,000 common shares through Merrill Lynch on NASDAQ with an approximate aggregate market value of $673,000. The filing lists total shares outstanding as 74,648,992 and shows the securities were acquired under Stock Plan Activity on 09/09/2025, with the intended sale date also 09/09/2025. The filer indicates there were no securities sold in the past three months by the reporting person. The notice includes the standard representation that the seller is not aware of any undisclosed material adverse information about the issuer.
CorMedix Inc. filed a Form 144 reporting a proposed sale of 53,997 common shares through Merrill Lynch on 09/09/2025. The filing lists an aggregate market value of $728,959.00 and indicates 74,648,992 shares outstanding for the issuer. The shares were acquired the same day (09/09/2025) under a stock plan activity from the issuer, with payment recorded as n/a. No securities were reported sold by the filer in the prior three months. The notice includes the standard statement that the seller does not possess undisclosed material adverse information and warns that false statements are criminally punishable.
CorMedix insider amendment reports a tax-withholding share disposition by Elizabeth Hurlburt, the company's Chief Operating Officer and a director. The filing shows 8,424 shares of common stock were withheld by the issuer at an effective price of $14.83 to satisfy the reporting person's tax liability, reducing her direct beneficial ownership to 176,990 shares. The Form 4/A amends an earlier filing to disclose this withheld amount. The disclosure is a mechanical equity withholding for taxes rather than an open-market sale and does not report derivative transactions.